Canaccord Genuity Remains a Buy on Natera (NTRA)

In a report released yesterday, Mark Massaro from Canaccord Genuity maintained a Buy rating on Natera (NTRA), with a price target of $27. The company’s shares closed yesterday at $20.63.

Massaro commented:

“We reiterate our BUY, and trim our PT to $27. Upcoming catalysts to own the stock for include: (1) revised ACOG bulletin supporting average-risk NIPT (we think is near-term and inevitable); (2) UNH and/or AET covering average-risk NIPT post the ACOG bulletin; (3) more partnerships ex-pharma; (4) more partnerships with pharma; (5) launch of Signatera LBs on cancer patients in ’19; (6) updates on kidney and launch in ’19; (7) launch of Panorama on QIAGEN GeneReader; (8) COGS reductions; (9) getting paid on microdeletions, and more. ACOG. NTRA indicated “new guidance is under way” which is “very supportive” of average risk NIPT, but we’re still waiting for ACOG to publish the new bulletin. NTRA is engaged with UNH and AET and we think their coverage policy decisions are inevitable. BMS, others roll in.”

According to, Massaro is a 5-star analyst with an average return of 17.3% and a 57.7% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Quanterix Corporation.

Natera has an analyst consensus of Strong Buy, with a price target consensus of $31.

See today’s analyst top recommended stocks >>

Based on Natera’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $33.82 million. In comparison, last year the company had a GAAP net loss of $27.12 million.

Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception, and Non-Invasive Paternity Testing.